Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab.

Kimberly M LauIla M SaundersAaron M Goodman

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Extramedullary relapse occurs frequently following treatment of B-ALL with blinatumomab. Further studies aimed at preventing extramedullary relapse following blinatumomab treatment are warranted.

Keyphrases

acute lymphoblastic leukemia
allogeneic hematopoietic stem cell transplantation
free survival
acute myeloid leukemia
replacement therapy